BRD4 and ovarian carcinoma: Concomitant BRD4 inhibition with PARP inhibitor [29], cisplatin [30], tyrosine kinase inhibitors [31,32], and MEK inhibitors [26,33] has been shown to efficiently and synergistically suppress ovarian carcinoma growth.